Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

<< Previous

Bullboard Posts

Next >>

Post by shareswapperon Apr 17, 2020 5:30pm

241 Views

Post# 30923914

ICO Has Legs

There's no way they brought Kish back just to add a headcount, something's up with respect to ICO-019 partnering. If we land a Phase II partner this could go to $.30 easy. Remember, Phase II is the final Trials, no Phase III require as it's not an NDA, it's an accelerated approval. Just bioequivalence efficacy required ...... Think I'll take a bunch more next week. Good weekend Longs, stay safe!!!

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project